Trial Profile
Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TRASTYVERE
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2014 Status changed from recruiting to active, no longer recruiting according to results presented at the 37th Annual San Antonio Breast Cancer Symposium.
- 28 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Oct 2014 as reported by ClinicalTrial.gov record.